Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 3/20 | 0.45 |
| ▸ | MMP3 | P08254 | 8/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | SELE | P16581 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 2/20 | 0.35 |
| ▸ | SELP | P16109 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 9/20 | 0.35 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23849114 | 0.96 | BIRC2 (0.45) | BIRC2MMP3MMP9SELESELL | |
| SCHEMBL23833843 | 0.90 | PLA2G2A (0.43) | BIRC2MMP3MMP9MMP2MMP1 | |
| SCHEMBL23833842 | 0.90 | PLA2G2A (0.43) | BIRC2MMP3MMP9MMP2MMP1 | |
| SCHEMBL25508499 | 0.89 | BIRC2 (0.43) | BIRC2MMP3MMP9SELLSELP | |
| SCHEMBL25508399 | 0.89 | BIRC2 (0.38) | BIRC2MMP3MMP9MMP1 | |
| SCHEMBL25508328 | 0.87 | BIRC2 (0.38) | BIRC2MMP3MMP9MMP1 | |
| SCHEMBL23834175 | 0.86 | PLA2G2A (0.43) | BIRC2MMP3MMP9MMP2MMP1 | |
| SCHEMBL23834176 | 0.86 | PLA2G2A (0.43) | BIRC2MMP3MMP9MMP2MMP1 | |
| SCHEMBL25508578 | 0.85 | BIRC2 (0.43) | BIRC2MMP3MMP9MMP1 | |
| SCHEMBL25508478 | 0.85 | BIRC2 (0.43) | BIRC2MMP3MMP9SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | BIRC2 3019/4885MMP3 1450/4885MMP9 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.